Aktuellt
SENASTE
The local and regional peer company, Arocell, withdrew the FDA application and may reapply a De Novo submission in due course. This has triggered a sharp negative reaction of 7-8% in Biovica. This is, in our view, a partly understandable negative overreaction. Our value proposition for Biovica remains a base case value of SEK 95 (Bull SEK 325 and Bear SEK 20).
LÄS MER
